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Background-—Diabetes mellitus frequently coexists with heart failure (HF), but few studies have compared the associations
between diabetes mellitus and cardiac remodeling, quality of life, and clinical outcomes, according to HF phenotype.
Methods and Results-—We compared echocardiographic parameters, quality of life (assessed by the Kansas City Cardiomyopathy
Questionnaire), and outcomes (1-year all-cause mortality, cardiovascular mortality, and HF hospitalization) between HF patients
with and without type 2 diabetes mellitus in the prospective ASIAN-HF (Asian Sudden Cardiac Death in Heart Failure) Registry, as
well as community-based controls without HF. Adjusted Cox proportional hazards models were used to assess the association of
diabetes mellitus with clinical outcomes. Among 5028 patients with HF and reduced ejection fraction (HFrEF; EF <40%) and 1139
patients with HF and preserved EF (HFpEF; EF ≥50%), the prevalences of type 2 diabetes mellitus were 40.2% and 45.0%,
respectively (P=0.003). In both HFrEF and HFpEF cohorts, diabetes mellitus (versus no diabetes mellitus) was associated with
smaller indexed left ventricular diastolic volumes and higher mitral E/e0 ratio. There was a predominance of eccentric hypertrophy
in HFrEF and concentric hypertrophy in HFpEF. Patients with diabetes mellitus had lower Kansas City Cardiomyopathy
Questionnaire scores in both HFpEF and HFrEF, with more prominent differences in HFpEF (Pinteraction<0.05). In both HFpEF and
HFrEF, patients with diabetes mellitus had more HF rehospitalizations (adjusted hazard ratio, 1.27; 95% CI, 1.05–1.54; P=0.014)
and higher 1-year rates of the composite of all-cause mortality/HF hospitalization (adjusted hazard ratio, 1.22; 95% CI, 1.05–1.41;
P=0.011), with no differences between HF phenotypes (Pinteraction>0.05).
Conclusions-—In HFpEF and HFrEF, type 2 diabetes mellitus is associated with smaller left ventricular volumes, higher mitral E/e0
ratio, poorer quality of life, and worse outcomes, with several differences noted between HF phenotypes.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01633398. ( J Am Heart Assoc. 2019;8:
e013114. DOI: 10.1161/JAHA.119.013114.)
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T he prevalence of diabetes mellitus has increased world-wide during the past 3 decades, with the largest
projected increases occurring in Asia.1 Diabetes mellitus
increases the risk of developing heart failure (HF), and
patients with both conditions are known to have particularly
poor outcomes.2
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Most previous studies of diabetesmellitus and HF have focused
on Western populations, and data on the relationship between
diabetes mellitus and HF phenotypes in Asia are lacking.2
Knowledge gleaned from Western cohorts may not be readily
extrapolated toAsians, particularly in light of recent studiesshowing
distinct differences between Asians and white populations.3,4
The effect of diabetes mellitus on cardiac remodeling is
uncertain, with studies showing potential development of
either dilated or restrictive left ventricular (LV) phenotypes
with diabetes mellitus.5 Data on how LV remodeling patterns
with diabetes mellitus differ between patients with HF with
reduced ejection fraction (HFrEF) versus those with preserved
ejection fraction (HFpEF) are scarce. We are not aware of any
prior study having concurrent comparative echocardiographic
findings in normal controls, patients with HFpEF, and patients
with HFrEF with and without diabetes mellitus.
Using data from the multinational ASIAN-HF (Asian Sudden
Cardiac Death in Heart Failure) Registry and community-based
controls without HF, we aim to examine the association
between type 2 diabetes mellitus and the key domains of
cardiac remodeling, quality of life (QoL), and clinical out-
comes, in patients with both HFpEF and HFrEF. In addition, we
aim to study the interactions between diabetes mellitus and
HF phenotype on these domains.
Methods
The study data and materials used to conduct the research
cannot be made available to other researchers, for purposes of
reproducing the results or replicating the procedure, because of
the legal restrictions imposed by multinational jurisdictions.
Study Population
Details of the ASIAN-HF Registry have been published in detail.6
In brief, the ASIAN-HF Registry is a prospective, observational,
multinational registry of Asian patients, aged >18 years, with
symptomatic HF (at least one documented episode of decom-
pensatedHF in the previous 6 months that resulted in a hospital
admission or equivalent treatment). Eligible patients were
enrolled from 46medical centers across 11 Asian regions using
uniform protocols and standardized procedures, with all data
captured in an electronic database. Data collection included
demographic variables, clinical symptoms, functional status,
QoL scores, cardiovascular history, and clinical risk factors.
Patients in the ASIAN-HF Registry were recruited in 2 stages:
those with HFrEF were enrolled between October 2012 and
December 2015, overlapping with recruitment of those with
HFpEF, between September 2013 and October 2016. Recruit-
ment of patients with HFpEF started later than the recruitment
of patients with HFrEF, for funding reasons. However, the delay
was only 1 year. Hence, we do not anticipate substantial shifts
in epidemiological features or treatment of patients with HFrEF
or HFpEF during this year to bias regional patterns of
multimorbidity, although this cannot be entirely excluded.
Type 2 diabetes mellitus was defined as the presence of the
clinical diagnosis (fasting plasma glucose ≥7 mmol/L, random
plasma glucose ≥11.1 mmol/L, or glycated hemoglobin ≥6.5%)
or a self-reported history of diabetes mellitus and/or receiving
antidiabetic therapy at baseline. Transthoracic echocardiogra-
phy and 12-lead electrocardiography were performed by
protocol at baseline. Patients with HFrEF were defined as those
with EF <40%, whereas patients with HFpEF were defined as
those with an EF ≥50% on baseline echocardiography. In
addition to history of HF decompensation within 6 months and
presence of typical symptoms and signs of HF, 99.5% of
patients with HFpEF had echocardiographic evidence for
diastolic dysfunction (E/e0 ≥13, E0 medial/lateral <9 ms, left
atrial (LA) enlargement, or LV hypertrophy [LVH]).7 Patients
were followed up for the outcomes of death and hospitalization,
which were independently adjudicated by a clinical end point
committee using prespecified criteria.6
Community-based controls without HF (n=965, 84 with
diabetes mellitus) were recruited as part of the control arm of
the SHOP (Singapore Heart Failure Outcomes and Pheno-
types) study.8 Controls were free-living adults without HF,
identified from the general community of Singapore, using
random sampling by door-to-door census of all residents in 5
designated precincts of Singapore. Controls underwent a
detailed clinical examination as well as echocardiography.
Both patients and controls provided informed consent, and
ethics approvals were obtained from the local Institutional
Review Board of each participating center.
Echocardiography
The echocardiography protocol has been published.6 Briefly,
echocardiography was performed at each center according to
Clinical Perspective
What Is New?
• Type 2 diabetes mellitus is associated with smaller left
ventricular volumes and higher mitral E/e0 ratio in patients
with heart failure.
• Type 2 diabetes mellitus impacts negatively on quality of life
and cardiovascular outcomes in patients with heart failure.
• Distinct differences are noted between heart failure pheno-
types.
What Are the Clinical Implications?
• Primary prevention and treatment interventions are needed
to tackle this twin scourge of disease.
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international guidelines, with a core laboratory providing
detailed imaging protocols, training, oversight, and quality
assurance, ensuring the accuracy and reproducibility of
results.6 Echocardiographic parameters captured included
LV dimensions and volume, LVEF, wall thickness, LA volumes,
and LV mass. These were indexed to body surface area and
measured according to published guidelines.9 Relative wall
thickness (RWT) was calculated as follows: (29diastolic
posterior wall thickness)/diastolic LV internal diameter. LVH
was defined as indexed LV mass index >115 g/m2 in men
and >95 g/m2 in women.9 Normal cardiac geometry was
defined as having no LVH and an RWT ≤0.42. Abnormal LV
geometry was categorized as concentric remodeling (no LVH
and RWT >0.42), eccentric hypertrophy (LVH and RWT ≤0.42),
and concentric hypertrophy (LVH and RWT >0.42), as per
guidelines.9
Health-Related QoL
The Kansas City Cardiomyopathy Questionnaire (KCCQ) was
used to assess the health-related QoL. The KCCQ is a 23-item,
self-administered questionnaire assessing the domains of
physical function, symptoms, social function, self-efficacy and
knowledge, and QoL; it is validated in multiple HF-related
disease states and in several languages.10 An overall
summary score can be derived from each domain, with
scores ranging from 0 to 100 (higher scores indicate better
health status).10 Non–English-speaking participants used
certified versions of the KCCQ translated into their native
languages.10
Outcomes
The principal outcomes evaluated were all-cause mortality and
the composite of all-cause mortality or HF hospitalization,
each at 1 year. Secondary outcomes included cardiovascular
mortality and HF hospitalization at 1 year. Causes of cardio-
vascular death were further subclassified as attributable to
sudden cardiac death (SCD), HF, acute myocardial infarction,
stroke, other or presumed cardiovascular death.
Statistical Analyses
Analyses were performed separately in patients with HFrEF
and HFpEF. Descriptive statistics were used to present
baseline characteristics in patients with and without diabetes
mellitus and included means and SDs, numbers and percent-
ages, or medians and interquartile ranges. Correspondingly,
differences between patients with and without diabetes
mellitus were compared by Student t test, v2 test, or
Wilcoxon rank sum test, as appropriate. Multivariable logis-
tic regression was performed to identify independent
demographic and clinical associates of diabetes mellitus,
including variables significant on univariable analysis and a
priori selection of variables based on clinical significance.
These variables included the following: age, sex, ethnicity,
regional income, heart rate, body mass index (BMI), chronic
kidney disease, hypertension, history of coronary artery
disease, atrial fibrillation, prior stroke, and peripheral arterial
disease. KCCQ scores were similarly adjusted for demo-
graphic factors, clinical variables, and medications and
presented as adjusted (marginal) means and associated
SEMs. Cox proportional hazards models were used to assess
the association of diabetes mellitus with clinical outcomes
and further adjusted for confounders in the overall group. No
violation of the proportionality hazards assumption for Cox
models was observed with the use of statistical tests and
graphical diagnostics (based on the Schoenfeld residuals).
Competing risks of death were accounted for in the analysis
of HF hospitalizations. The time to outcome in Cox regression
was defined as the time from baseline visit to the event of
interest (eg, death or hospitalization for HF) and censored at
the last visit or 1 year, whichever was earlier. Cox models
were adjusted for age, sex, ethnicity, regional income,
enrollment type, HF group, systolic blood pressure, heart
rate, BMI, history of coronary artery disease, atrial fibrillation,
peripheral arterial disease, chronic kidney disease, retinopa-
thy, neuropathy, obstructive pulmonary disease, and use of HF
medications.
The associations of QoL, echocardiographic features, and
outcomes with diabetes mellitus were tested for interactions
to assess if these relationships differed between HFrEF and
HFpEF. Interaction analyses were also performed between
diabetes mellitus and the following: (1) ethnicity as a factor
variable, (2) BMI as a continuous variable, and (3) national
income level as a factor variable for the respective outcomes,
where national income level was as defined by the World
Health Organization (lower: Indonesia, Philippines, and India;
middle: China, Thailand, and Malaysia; higher: Singapore,
Hong Kong, Taiwan, South Korea, and Japan). Stratified
analyses were performed if interactions were significant. All
statistical analyses were performed using Stata, version 14.0
(StataCorp). P≤0.05 was considered statistically significant;
all tests were performed 2 sided.
Results
Prevalence of Diabetes Mellitus
Of a total of 6167 patients in the ASIAN-HF Registry, 5028 had
HFrEF (mean age, 60.013.1 years; 78.2% men; LVEF, 27.3
7.1%) and 1139 had HFpEF (mean age, 68.712.3 years;
50.3% men; LVEF, 61.07.2%). The prevalence of type 2
diabetes mellitus was higher in those with HFpEF (45.0%)
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Table 1. Baseline Characteristics of the Study Population
Characteristics
HFrEF HFpEF
Total
Diabetes
Mellitus
No Diabetes
Mellitus Total
Diabetes
Mellitus
No Diabetes
Mellitus P Value
No. 5028 2021 3007 . . . 1139 513 626 . . .
Duration of
diabetes mellitus
. . . 9.8 (8.2)* . . . . . . . . . 12.0 (8.3)† . . . . . .
Demographics
Age, y 60.0 (13.1) 61.9 (10.9) 58.8 (14.3) <0.001 68.7 (12.3) 69.4 (10.8) 68.1 (13.4) 0.081
Women 1095 (21.8) 425 (21.0) 670 (22.3) 0.290 566 (49.7) 262 (51.1) 304 (48.6) 0.400
Ethnicity <0.001 <0.001
Chinese 1513 (30.1) 618 (30.6) 895 (29.8) 579 (50.8) 271 (52.8) 308 (49.2)
Indian 1567 (31.2) 649 (32.1) 918 (30.5) 275 (24.1) 102 (19.9) 173 (27.6)
Malay 790 (15.7) 391 (19.3) 399 (13.3) 124 (10.9) 89 (17.3) 35 (5.6)
Japanese 523 (10.4) 161 (8.0) 362 (12.0) 117 (10.3) 37 (7.2) 80 (12.8)
Korean 304 (6.0) 91 (4.5) 213 (7.1) 35 (3.1) 6 (1.2) 29 (4.6)
Thai 167 (3.3) 58 (2.9) 109 (3.6) 4 (0.4) 4 (0.8) 0 (0.0)
Filipino 46 (0.9) 13 (0.6) 33 (1.1) 4 (0.4) 3 (0.5) 1 (0.2)
Indigenous 105 (2.1) 34 (1.7) 71 (2.4) 1 (0.1) 1 (0.2) 0 (0.0)
Others 13 (0.3) 6 (0.3) 7 (0.2)
Geographical region <0.001 <0.001
Northeast Asia 1605 (31.9) 511 (25.3) 1094 (36.4) 531 (46.6) 209 (40.7) 322 (51.4)
South Asia 1361 (27.1) 493 (24.4) 868 (28.9) 220 (19.3) 62 (12.1) 158 (25.2)
Southeast Asia 2062 (41.0) 1017 (50.3) 1045 (34.7) 388 (34.1) 242 (47.2) 146 (23.3)
Economic
development
<0.001 <0.001
Low income 1721 (34.2) 616 (30.5) 1105 (36.8) 239 (21.0) 72 (14.0) 167 (26.7)
Middle income 1155 (23.0) 424 (21.0) 731 (24.3) 73 (6.4) 45 (8.8) 28 (4.5)
High income 2152 (42.8) 981 (48.5) 1171 (38.9) 827 (72.6) 396 (77.2) 431 (68.9)
Clinical characteristics
NYHA 0.036 0.140
Class I 588 (12.8) 242 (13.2) 346 (12.5) 153 (16.3) 62 (13.9) 91 (18.6)
Class II 2406 (52.3) 938 (51.3) 1468 (53.0) 556 (59.3) 265 (59.3) 291 (59.4)
Class III 1324 (28.8) 555 (30.3) 769 (27.7) 202 (21.6) 107 (23.9) 95 (19.4)
Class IV 282 (6.1) 94 (5.1) 188 (6.8) 26 (2.8) 13 (2.9) 13 (2.6)
Shortness of breath
on exertion
3770 (75.0) 1485 (73.6) 2285 (76.0) 0.050 683 (60.0) 334 (65.1) 349 (55.8) 0.001
Shortness of
breath at rest
926 (18.4) 399 (19.8) 527 (17.5) 0.046 135 (11.9) 72 (14.0) 63 (10.1) 0.039
Reduction in exercise
tolerance
3531 (70.3) 1376 (68.2) 2155 (71.7) 0.008 673 (59.1) 334 (65.1) 339 (54.2) <0.001
Nocturnal cough 923 (18.4) 374 (18.5) 549 (18.3) 0.820 148 (13.0) 77 (15.0) 71 (11.3) 0.067
Orthopnea 1135 (22.6) 492 (24.4) 643 (21.4) 0.013 174 (15.3) 94 (18.3) 80 (12.8) 0.010
Paroxysmal nocturnal
dyspnea
955 (19.0) 404 (20.0) 551 (18.3) 0.140 120 (10.5) 61 (11.9) 59 (9.4) 0.180
Continued
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Table 1. Continued
Characteristics
HFrEF HFpEF
Total
Diabetes
Mellitus
No Diabetes
Mellitus Total
Diabetes
Mellitus
No Diabetes
Mellitus P Value
Elevated jugular
venous pressure
777 (15.5) 377 (18.7) 400 (13.3) <0.001 118 (10.4) 71 (13.8) 47 (7.5) >0.001
S3 present 501 (10.0) 199 (9.8) 302 (10.1) 0.810 23 (2.0) 10 (1.9) 13 (2.1) 0.880
Peripheral edema 1186 (23.6) 582 (28.8) 604 (20.1) <0.001 374 (32.9) 213 (41.6) 161 (25.7) <0.001
Pulmonary rales
present
839 (16.7) 405 (20.0) 434 (14.4) <0.001 175 (15.4) 105 (20.5) 70 (11.2) <0.001
Hepatomegaly 277 (5.5) 112 (5.5) 165 (5.5) 0.940 28 (2.5) 10 (1.9) 18 (2.9) 0.320
Hepatojugular
reflux positive
436 (8.7) 198 (9.8) 238 (7.9) 0.021 71 (6.2) 43 (8.4) 28 (4.5) 0.007
LV ejection
fraction, %
27.3 (7.1) 27.4 (7.1) 27.2 (7.1) 0.300 61.0 (7.2) 60.9 (7.3) 61.1 (7.2) 0.650
Systolic blood
pressure, mm Hg
118.3 (20.1) 120.9 (20.2) 116.6 (19.8) <0.001 132.2 (22.1) 135.2 (22.2) 129.8 (21.7) <0.001
Diastolic blood
pressure, mm Hg
72.4 (12.6) 72.3 (12.3) 72.4 (12.8) 0.690 72.5 (12.9) 71.3 (12.2) 73.5 (13.4) 0.004
Heart rate, bpm 79.6 (16.2) 80.2 (16.0) 79.2 (16.3) 0.029 76.1 (15.2) 76.3 (13.9) 76.0 (16.2) 0.770
Body mass index,
kg/m2
24.9 (5.1) 25.5 (4.9) 24.4 (5.2) <0.001 27.1 (6.0) 28.4 (6.1) 26.0 (5.8) <0.001
BMI categories, kg/m2 <0.001 <0.001
Underweight (<18.5) 320 (6.7) 77 (4.0) 243 (8.5) 29 (3.2) 3 (0.7) 26 (5.3)
Normal (18.5–23) 1501 (31.3) 538 (27.9) 963 (33.6) 194 (21.3) 67 (16.1) 127 (25.7)
Overweight (23–27.5) 1844 (38.4) 774 (40.1) 1070 (37.3) 325 (35.8) 140 (33.7) 185 (37.4)
Obese (≥27.5) 1134 (23.6) 542 (28.1) 592 (20.6) 361 (39.7) 205 (49.4) 156 (31.6)
eGFR, mL/min /1.73 m2 65.9 (27.8) 60.9 (27.8) 69.4 (27.3) <0.001 61.5 (28.8) 53.9 (27.4) 68.6 (28.2) <0.001
Comorbidities
Chronic kidney
disease (eGFR
[mL/min/1.73 m2] <60)
1745 (44.0) 884 (53.3) 861 (37.4) <0.001 461 (50.2) 268 (60.8) 193 (40.5) <0.001
Ischemic cause
of HF
2348 (46.7) 1244 (61.6) 1104 (36.8) <0.001 350 (30.9) 194 (38.0) 156 (25.0) <0.001
Hypertension 2580 (51.3) 1375 (68.1) 1205 (40.1) <0.001 811 (71.2) 438 (85.4) 373 (59.6) <0.001
Coronary artery
disease
2498 (49.7) 1301 (64.4) 1197 (39.8) <0.001 335 (29.5) 208 (40.5) 127 (20.4) <0.001
Atrial fibrillation 910 (18.1) 327 (16.2) 583 (19.4) 0.004 326 (28.6) 133 (25.9) 193 (30.8) 0.068
Prior stroke 325 (6.5) 173 (8.6) 152 (5.1) <0.001 95 (8.3) 47 (9.2) 48 (7.7) 0.360
Liver disease 168 (3.3) 64 (3.2) 104 (3.5) 0.570 23 (2.0) 13 (2.5) 10 (1.6) 0.260
Peripheral arterial
disease
167 (3.3) 107 (5.3) 60 (2.0) <0.001 23 (2.0) 16 (3.1) 7 (1.1) 0.016
Microvascular complications
Nephropathy . . . 298 (14.8) . . . . . . . . . 113 (22.0) . . . . . .
Retinopathy . . . 187 (9.3) . . . . . . . . . 64 (12.5) . . . . . .
Neuropathy . . . 117 (5.8) . . . . . . . . . 47 (9.2) . . . . . .
COPD 418 (8.3) 158 (7.8) 260 (8.7) 0.290 104 (9.1) 50 (9.7) 54 (8.6) 0.510
Continued
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compared with those with HFrEF (40.2%) (P=0.003), and the
average duration of diabetes mellitus was longer in those with
HFpEF (12.08.3 years) compared with those with HFrEF
(9.88.2 years) (P<0.001). In both HFrEF and HFpEF, patients
with diabetes mellitus were more likely to be from Southeast
Asia and the high-income regions (Table 1). Prevalence of type
2 diabetes mellitus was lowest in China (at 22.8%) and highest
in Singapore (at 58.2%) and Hong Kong (at 56.9%). Among 965
community-based controls without HF (mean age,
57.310.3 years; 48.7% men), 8.7% (n=84) had diabetes
mellitus.
Baseline Correlates of Diabetes Mellitus
In HFrEF, but not HFpEF (Table 1), patients with diabetes
mellitus were older than those without diabetes mellitus. In
both HFpEF and HFrEF, patients with diabetes mellitus had a
higher prevalence of overweight/obesity than those without
diabetes mellitus. Obesity was more prevalent in those with
HFpEF and diabetes mellitus than in those with HFrEF and
diabetes mellitus (49.4% versus 28.1%; P<0.001). Of note,
31.9% of patients with HFrEF (versus 16.8% of patients with
HFpEF) with diabetes mellitus were either normal weight or
underweight. In both HFrEF and HFpEF, patients with diabetes
mellitus also had a higher prevalence of chronic kidney
disease, hypertension, coronary artery disease, and peripheral
arterial disease, and were more likely to present with signs
and symptoms of HF, compared with those without diabetes
mellitus. Yet, compared with patients without diabetes
mellitus, those with diabetes mellitus were less likely to be
prescribed a mineralocorticoid receptor antagonist (in HFrEF
and HFpEF) and an angiotensin-converting enzyme inhibitor/
angiotensin II receptor blocker (in HFrEF), but more likely to
be given diuretics and as likely to be prescribed b-blockers (in
HFrEF and HFpEF). For anti–diabetes mellitus therapy, the
most commonly used medications in both HFrEF and HFpEF
were metformin, a sulfonylurea, insulin, and a dipeptidyl
peptidase-4 inhibitor. Table 2 shows the variables indepen-
dently correlated with diabetes mellitus in HFrEF and HFpEF.
In HFrEF, positive correlates included the following: older age,
Indian or Malay ethnicity, dwelling in a middle-/high-income
region, higher BMI, presence of chronic kidney disease,
hypertension, coronary artery disease, peripheral arterial
disease, and prior stroke. In contrast, patients of Japanese
or Korean descent (versus Chinese) and those with atrial
fibrillation were negatively associated with diabetes mellitus
in HFrEF. Independent correlates of diabetes mellitus in
HFpEF included the following: Indian or Malay ethnicity,
Table 1. Continued
Characteristics
HFrEF HFpEF
Total
Diabetes
Mellitus
No Diabetes
Mellitus Total
Diabetes
Mellitus
No Diabetes
Mellitus P Value
Smoking, ever 2267 (45.1) 942 (46.6) 1325 (44.1) 0.077 259 (22.8) 120 (23.4) 139 (22.2) 0.620
Alcohol, ever 1467 (29.2) 564 (27.9) 903 (30.0) 0.100 170 (15.0) 81 (15.9) 89 (14.2) 0.440
Medications
ACEI or ARB 3705 (75.2) 1439 (72.3) 2266 (77.2) <0.001 669 (66.8) 327 (69.1) 342 (64.7) 0.130
b Blockers 3798 (77.1) 1542 (77.5) 2256 (76.9) 0.610 676 (67.5) 326 (68.9) 350 (66.2) 0.350
Diuretics 4038 (82.0) 1693 (85.1) 2345 (79.9) <0.001 709 (70.8) 356 (75.3) 353 (66.7) 0.003
MRA 2878 (58.4) 1079 (54.2) 1799 (61.3) <0.001 214 (21.4) 76 (16.1) 138 (26.1) <0.001
Antidiabetic
medications
. . . 1307 (66.5) . . . . . . . . . 335 (68.4) . . . . . .
Metformin . . . 692 (35.2) . . . . . . . . . 154 (31.4) . . . . . .
Sulfonylureas . . . 705 (35.9) . . . . . . . . . 170 (34.7) . . . . . .
Gliptins . . . 227 (11.6) . . . . . . . . . 76 (15.5) . . . . . .
a-Glucosidase
inhibitors
. . . 134 (6.8) . . . . . . . . . 24 (4.9) . . . . . .
Meglitinides . . . 24 (1.2) . . . . . . . . . 8 (1.6) . . . . . .
Insulins . . . 327 (16.6) . . . . . . . . . 103 (21.0) . . . . . .
Data are given as number (percentage) or mean (SD). ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; bpm, beats per
minute; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HF, heart failure; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced
ejection fraction; LV, left ventricular; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.
*Duration of diabetes mellitus reported in n=1339 patients with HFrEF.
†
Duration of diabetes mellitus reported in n=344 patients with HFpEF.
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dwelling in a high-income region, higher BMI, and presence of
chronic kidney disease, hypertension, or coronary artery
disease.
Diabetes Mellitus and Cardiac Remodeling
Among controls without HF, diabetes mellitus was associated
with thicker LV walls, smaller indexed LV end-diastolic and
end-systolic volumes, higher E/e0 ratio, and greater preva-
lence of abnormal LV geometry (concentric LV remodeling,
concentric hypertrophy, and eccentric hypertrophy), com-
pared with those without diabetes mellitus (Table 3).
Among patients with HFrEF, diabetes mellitus (versus no
diabetes mellitus) was associated with smaller indexed LV
end-diastolic and end-systolic volumes, a higher E/e0 ratio,
but similar LV wall thickness. These associations persisted
after correcting for age, sex, ethnicity, and hypertension
(P<0.001 for indexed LV end-diastolic and end-systolic
volumes and E/e0 ratio; P=0.434 for LV wall thickness). The
most common LV geometry present in patients with HFrEF
was eccentric hypertrophy. There were no significant
interactions between income level (P=0.526), ethnicity
(P=0.580), or BMI (P=0.195) with diabetes mellitus on its
association with LV geometry.
Among patients with HFpEF, diabetes mellitus (versus no
diabetes mellitus) was also associated with a thicker LV wall,
smaller indexed LV end-diastolic volumes, and higher mitral
E/e0 ratio but smaller indexed LA volumes. These associations
persisted after adjusting for the confounders above (P=0.037,
P=0.017, P=0.029, and P=0.002 for LV wall thickness,
indexed LV end-diastolic volumes, E/e0 ratio, and indexed
LA volume, respectively). The predominant geometry was
concentric hypertrophy. There were no significant interactions
between income level (P=0.567), ethnicity (P=0.763), or BMI
(P=0.197) with diabetes mellitus on its association with LV
geometry (Table 3 and Figure 1).
Diabetes Mellitus and Health-Related QoL
Compared with those without diabetes mellitus, patients with
diabetes mellitus in both HF phenotypic groups had worse
QoL (lower physical limitation score, symptom burden and
Table 2. Clinical Correlates of Diabetes Mellitus
Variable
HFrEF HFpEF
Adjusted Odds Ratio
(95% CI)* P Value
Adjusted Odds Ratio
(95% CI)* P Value
Age, y 1.011 (1.004–1.017) 0.002 0.999 (0.984–1.016) 0.745
Women 1.10 (0.92–1.32) 0.297 0.99 (0.71–1.39) 0.953
Ethnicity
Chinese 1.00 (Reference)  1.00 (Reference) 
Indian 2.86 (2.13–3.84) <0.001 1.98 (0.96–4.13) 0.066
Malay 1.96 (1.54–2.51) <0.001 2.53 (1.39–4.60) 0.002
Japanese/Korean 0.66 (0.53–0.82) <0.001 0.64 (0.39–1.05) 0.076
Economic development
Low income 1.00 (Reference)  1.00 (Reference) 
Middle income 1.64 (1.22–2.21) 0.001 1.66 (0.52–5.32) 0.393
High income 3.01 (2.28–3.97) <0.001 3.06 (1.39–6.73) 0.005
Heart rate, bpm 1.008 (1.003–1.013) 0.001 0.999 (0.988–1.011) 0.928
Body mass index, kg/m2 1.042 (1.027–1.058) <0.001 1.051 (1.020–1.083) 0.001
Chronic kidney disease 1.48 (1.27–1.72) <0.001 1.86 (1.32–2.61) <0.001
Hypertension 2.32 (2.00–2.69) <0.001 2.64 (1.72–4.06) <0.001
Coronary artery disease 2.21 (1.89–2.57) <0.001 1.92 (1.33–2.76) 0.001
Atrial fibrillation 0.78 (0.65–0.95) 0.012 0.76 (0.53–1.10) 0.149
Prior stroke 1.34 (1.01–1.76) 0.039 0.66 (0.37–1.19) 0.167
Peripheral arterial disease 1.87 (1.27–2.76) 0.002 2.88 (0.71–11.7) 0.139
Bpm indicates beats per minute; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
*Adjusted for age, sex, ethnicity, regional income, heart rate, body mass index, chronic kidney disease, hypertension, history of coronary artery disease, atrial fibrillation, prior stroke, and
peripheral arterial disease.
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total symptom score, social limitation, and clinical sum-
mary and overall summary KCCQ scores) (Table 4). There
were significant interactions between diabetes melli-
tus and HF phenotype for physical limitation score
(Pinteraction=0.002), QoL score (Pinteraction=0.001), social
limitation (Pinteraction=0.001), clinical summary score
(Pinteraction=0.006), and overall summary score (Pinteraction=0.001),
indicating that the extent to which diabetes mellitus affected
these QoL domains differed by HF phenotype. For the clinical
and overall summary scores, scores were lower in those with
diabetes mellitus (compared with those without diabetes
mellitus) in both HFrEF and HFpEF, with more prominent
differences in HFpEF.
Diabetes Mellitus and Clinical Outcomes
Of 6167 patients, 5584 (90.5%) had outcome data available,
whereas 583 (9.5%) were lost to follow-up. Compared with
patients without diabetes mellitus, those with type 2 diabetes
mellitus had a higher 1-year composite of all-cause mortality/
HF hospitalizations (hazard ratio [HR], 1.63; 95% CI, 1.45–
1.84; P<0.001; and adjusted HR, 1.22; 95% CI, 1.05–1.41;
P=0.011) on univariable and multivariable analysis, respec-
tively. There was higher 1-year overall mortality (HR, 1.37;
95% CI, 1.16–1.62; P<0.001), but this association was
attenuated in multivariable analysis (adjusted HR, 1.08; 95%
CI, 0.87–1.35; P=0.473). For secondary outcomes, the
findings for cardiovascular mortality were similar to the above
results on overall mortality. However, patients with diabetes
mellitus (versus no diabetes mellitus) had a higher risk
of HF rehospitalization at 1 year (adjusted HR, 1.27; 95% CI,
1.05–1.54; P=0.014). HF phenotype did not modify these
relationships (Pinteraction>0.05). SCD and HF death were the
most common modes of cardiovascular death among those
with diabetes mellitus (26.3% for SCD death, and 20.1% for HF
death), as well as those without diabetes mellitus (30.6% SCD
death, and 26.0% for HF death), with no difference between
phenotypes (Pinteraction>0.05) (Table 5 and Figure 2).
Discussion
We provide the first multinational prospective data from Asia
describing the association between diabetes mellitus and key
aspects of HF, including cardiac remodeling, QoL, and clinical
outcomes, among patients with HFpEF and HFrEF. Our main
findings were as follows: (1) The prevalence of type 2 diabetes
mellitus was high among Asian patients with HF, especially
those with HFpEF, with notable regional variation. Different
correlates of diabetes mellitus were noted for both HFpEF and
HFrEF. (2) Type 2 diabetes mellitus was associated with smaller
indexed LV diastolic volumes and higher LV filling pressure
(higher mitral E/e0 ratio) compared with patients without
diabetes mellitus, in both HFrEF and HFpEF. However, there
were differences in cardiac remodeling, with predominance of
eccentric hypertrophy in HFrEF and concentric hypertrophy in
HFpEF. (3) Compared with patients without diabetes mellitus,
those with diabetes mellitus had worse QoL, with the difference
more prominent in HFpEF than HFrEF, at least for some KCCQ
domains. (4) Type 2 diabetes mellitus was associated with a
higher risk of the composite outcome of all-cause mortality or
HF hospitalization at 1 year, driven mainly by a higher rate of
HF hospitalization. The relationships between diabetes mellitus
and outcome were similar in HFrEF and HFpEF.
Figure 1. Left ventricular geometry by heart failure (HF) type and type 2 diabetes mellitus
(T2DM). HFpEF indicates HF with preserved ejection fraction; HFrEF, HF with reduced ejection
fraction.
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Cardiac Remodeling
Among controls without HF, diabetes mellitus was associated
with greater LV wall thickness and abnormal LV cardiac
remodeling. Similar findings have been described in several
population-based studies.11 Several explanatory mechanisms
have been postulated, including the prohypertrophic effects of
insulin, insulin growth factor-1, and insulin resistance.12 In the
initial insulin-resistant phase of diabetes mellitus, circulating
insulin levels are increased. Insulin is known to directly
stimulate cardiomyocyte growth13 and indirectly via binding
to the insulin growth factor-1 receptor.14 Insulin growth factor-
1 itself is known to stimulate the growth of cardiac myocytes
through induction of cardiac protein synthesis.15 We also found
Table 4. KCCQ Scores by Diabetic Status
Quality-of-Life Domains
Pinteraction (Diabetes
Mellitus9HF Group)
HFrEF HFpEF
Diabetes
Mellitus
No Diabetes
Mellitus P Value
Diabetes
Mellitus
No Diabetes
Mellitus P Value
Physical limitation score 0.002 66.5 (0.6) 68.8 (0.5) 0.007 70.6 (1.2) 77.8 (1.1) <0.001
Symptom stability score 0.048 63.1 (0.7) 63.6 (0.6) 0.597 56.4 (1.4) 59.3 (1.3) 0.139
Symptom frequency score 0.141 66.6 (0.7) 69.4 (0.5) 0.001 68.0 (1.5) 73.0 (1.3) 0.014
Symptom burden score 0.054 70.1 (0.6) 72.2 (0.5) 0.015 75.1 (1.2) 80.0 (1.1) 0.004
Total symptom score 0.081 68.3 (0.6) 70.8 (0.5) 0.003 71.6 (1.3) 76.5 (1.1) 0.005
Self-efficacy score 0.050 64.3 (0.7) 64.8 (0.5) 0.584 65.4 (1.4) 68.4 (1.3) 0.124
Quality-of-life score 0.001 55.8 (0.6) 56.7 (0.5) 0.259 64.4 (1.2) 69.8 (1.1) 0.001
Social limitation score 0.001 59.8 (0.8) 63.1 (0.7) 0.003 70.2 (1.6) 79.5 (1.5) <0.001
Overall summary score 0.001 62.8 (0.6) 65.0 (0.4) 0.004 69.1 (1.1) 75.8 (1.0) <0.001
Clinical summary score 0.006 67.5 (0.6) 69.9 (0.4) 0.001 70.9 (1.1) 77.0 (1.0) <0.001
Data are presented as adjusted mean (SE). Adjusted for age, sex, ethnicity, regional income, hypertension, systolic blood pressure, heart rate, ejection fraction, obstructive pulmonary
disease, atrial fibrillation, peripheral arterial disease, coronary artery disease, educational status, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, b blockers,
and diuretics. HF indicates heart failure; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; KCCQ, Kansas City Cardiomyopathy Questionnaire.
Table 5. Clinical Outcomes
1-y Outcomes
No. (%) of Events
Crude Hazard
Ratio (95% CI) P Value Pinteraction (DM9HF Group)
Adjusted Hazard
Ratio (95% CI)* P ValueDM (N=2322) No DM (N=3262)
All-cause mortality 262 (11.3) 274 (8.4) 1.37 (1.16–1.62) <0.001 0.271 1.08 (0.87–1.35) 0.473
HFrEF 235/1849 242/2680 . . . . . . . . .
HFpEF 27/473 32/582 . . . . . . . . .
Cardiovascular
mortality
222 (9.6) 233 (7.1) 1.36 (1.13–1.64) 0.001 0.326 1.07 (0.83–1.36) 0.603
HFrEF 203/1849 210/2680 . . . . . . . . .
HFpEF 19/473 23/582 . . . . . . . . .
All-cause
mortality/HF
hospitalizations
561 (24.2) 511 (15.7) 1.63 (1.45–1.84) <0.001 0.525 1.22 (1.05–1.41) 0.011
HFrEF 491/1849 451/2680 . . . . . . . . .
HFpEF 70/473 60/582 . . . . . . . . .
HF hospitalizations 356 (15.3) 292 (9.0) 1.79 (1.53–2.09) <0.001 0.648 1.27 (1.05–1.54) 0.014
HFrEF 306/1849 260/2680 . . . . . . . . .
HFpEF 50/473 32/582 . . . . . . . . .
DM indicates diabetes mellitus; HF, heart failure; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction.
*DM, adjusted for age, sex, ethnicity, regional income, enrollment type, HF group, systolic blood pressure, heart rate, body mass index, history of coronary artery disease, atrial fibrillation,
peripheral arterial disease, chronic kidney disease, retinopathy, neuropathy, obstructive pulmonary disease, and use of angiotensin-converting enzyme inhibitors/angiotensin II receptor
blockers, betablockers, mineralocorticoid receptor antagonists, and diuretics.
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greater LV diastolic dysfunction (higher mitral E/e0 ratio) in
controls with diabetes mellitus compared with those without
diabetes mellitus, consistent with other non-HF diabetic
cohorts.16 Increased LV thickness and stiffness, resulting from
lipotoxicity17 and myocardial deposition of collagen and
advanced glycation end products,16 may explain this finding.
We found differences in diabetic cardiac remodeling
between patients with HFrEF and HFpEF. Although there
were smaller indexed LV end-diastolic volumes and higher LV
filling pressures in patients with versus without diabetes
mellitus in both HF phenotypes, diabetes mellitus was
associated with preserved LV wall thickness and a predom-
inantly eccentric hypertrophy phenotype in HFrEF, in contrast
to LV wall thickening and a predominantly concentric
hypertrophy phenotype in HFpEF. Consistent with our
findings, patients with HFrEF and diabetes mellitus (versus
no diabetes mellitus) in the STICH (Surgical Treatment for
Ischemic Heart Failure) trial had higher E/E0 ratios and
smaller LV volumes18; however, patients with HFpEF and dia-
betes mellitus (versus no diabetes mellitus) in the I-PRESERVE
(Irbesartan in Heart Failure With Preserved Ejection Fraction)
trial had higher E/E0 ratios, thicker LV walls, and more LVH.19
Unlike our study, no prior studies have concomitantly included
both HF types or controls without HF from the same
population.
As recently described,5,20 the mechanisms by which diabetes
mellitus affects cardiac structure in HFrEF and HFpEF differ. In
HFrEF, diabetesmellitus causes increased cardiac cell deathwith
its attendant fibrosis. Cell death occurs as a result of several
pathways, including lipotoxicity and deposition of advanced
glycation end products.5,20 Lipotoxicity may occur from the
accumulation of triglycerides in the cardiac cells or the toxic
effects of excess circulating fatty acids.17,20 Advanced glycation
end products foster inflammation, immune cell infiltration, and
subsequent apoptosis.21 Intense replacement fibrosis follows
cell death because of the stimulation of protein kinase C activity
in fibroblasts by hyperglycemia.20 In HFpEF, cardiac cell
hypertrophy and stiffness may occur because of hyperinsuline-
mia13,14 as well as endothelial dysfunction resulting from
coronary microvascular disease seen in diabetes mellitus22 with
downstream lack of cGMP in the myocardium.20 This has been
corroborated by histological findings from LV endomyocardial
biopsies in which increased fibrosis and deposition of advanced
glycation end products were found in HFrEF, whereas increased
cardiomyocyte resting tension was observed in HFpEF.23 The
cardiac autonomic neuropathy seen in diabetes mellitus,
Figure 2. Survival by type 2 diabetes mellitus (DM) status for various outcomes at 1 year. HF indicates heart failure; HR, hazard
ratio.
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resulting from parasympathetic denervation and increased
sympathetic tone with high circulating catecholamines,24 has
also been shown to cause the increased LV wall stress, LVH, and
concentric remodeling25 seen in HFpEF.
In all 3 groups, diabetes mellitus appears to confer relative
“protection” from LV dilatation with diabetes mellitus, albeit
by different mechanisms (namely, from insulin signaling and
LVH in HFpEF versus cell death from lipotoxicity and its
attendant fibrosis in HFrEF). This is also seen in the left atria
of patients with HFpEF. The smaller LA volumes in HFpEF
with diabetes mellitus are potentially caused by the similar
inward remodeling of LA in the presence of diabetes mellitus
as with the LV. This is consistent with the lower atrial
fibrillation rates we found in patients with diabetes mellitus in
our study as well as other published cohorts.26 In BENEFICIAL
(A Double-Blind, Placebo-Controlled, Randomized Trial Evalu-
ating the Efficacy and Safety of Alagebrium [ALT-711] in
Patients With Chronic Heart Failure), alagebrium (an
advanced glycation end products cross-link breaker) was
associated with a trend toward LV dilatation in patients with
HFrEF (albeit nonsignificant), in contrast to a reduction in LV
end-diastolic diameter in those receiving placebo, suggesting
a role of AGE cross-links in protecting against LV dilation.27
There was also a trend toward worse exercise tolerance in
patients with HFrEF receiving alagebrium.27 Beyond HF, the
phenomenon of negative remodeling with diabetes mellitus
has also been described in other cardiovascular domains.
Epidemiologically, there exist not only strong links of an
inverse correlation between diabetes mellitus and abdominal
aorta dilation but also slower aneurysm enlargement and
fewer repairs for rupture in patients with diabetes melli-
tus.28,29 This paradoxically protective effect of diabetes
mellitus against aortic aneurysms, despite increased
atherosclerosis, may in part be explained by AGE cross-
linking because alagebrium therapy was associated with
aortic dilatation in elderly hypertensive dogs.30 Furthermore,
in coronary atherosclerosis, the expected positive (outward)
compensatory remodeling to maintain coronary blood flow in
the presence of obstruction is absent in diabetes mellitus,
with many studies showing a predominance of maladaptive
negative (inward) remodeling.31,32
Health-Related QoL
There is increasing recognition of the importance of patient-
centered outcomes in HF. In both HFrEF and HFpEF, patients
with diabetes mellitus had worse scores in most KCCQ
domains, compared with those without diabetes mellitus. In a
small study of 325 patients with HFpEF and HFrEF, diabetes
mellitus was similarly associated with poorer QoL, as
measured by the Minnesota Living With Heart Failure
Questionnaire.33 The difference between patients with and
without diabetes mellitus was more prominent across
domains in HFpEF compared with HFrEF. This could be
because either diabetes mellitus did not materially influence
the already low QoL scores in the generally more symp-
tomatic patients with HFrEF or diabetes with its attendant
systemic inflammatory effects plays a greater role in HFpEF
than HFrEF.
Clinical Outcomes
The attenuated association between diabetes mellitus and the
risk of all-cause mortality at 1 year is consistent with prior
studies. In the EFFECT (Enhanced Feedback for Effective
Cardiac Treatment) study, in which half of the cohort consisted
of patients with HFrEF, diabetes mellitus predicted 1-year
mortality in univariable, but not in multivariable, analysis.34
Likewise, in the OPTIMIZE-HF (Organized Program to Initiate
Lifesaving Treatment in Hospitalized Patients With Heart
Failure) Registry, in which approximately half the cohort had
HFrEF, diabetes mellitus did not predict 90-day mortality.35 A
similar lack of effect of diabetesmellitus on in-hospital mortality
was seen in ADHERE (Acute Decompensated Heart Failure
National Registry).36 However, diabetes mellitus was associ-
ated with significantly higher mortality in studies with longer
follow-up.37 The CHARM (Candesartan in Heart Failure: Assess-
ment of Reduction in Mortality and Morbidity) study found
diabetes mellitus to be a significant predictor of mortality,
regardless of EF, over amedian follow-up of 38 months.37 In the
I-PRESERVE trial in patients with HFpEF, with a median follow-
up of 4.1 years, diabetes mellitus was associated with higher
mortality.38 The finding that diabetes mellitus is not indepen-
dently predictive of death in the present study and other short-
term studies, but is with longer-term follow-up, suggests that
short-term mortality in patients with HF and diabetes mellitus
may be determined more by comorbidities and less by diabetes
mellitus itself; however, over longer-term follow-up, the dele-
terious effects of diabetesmellitusmay becomemore apparent.
Although there was no significant correlation with short-term
mortality, we found that diabetes mellitus was significantly
associated with HF hospitalizations at 1 year, regardless of HF
phenotype. Likewise, in the OPTIMIZE-HF Registry, diabetes
mellitus predicted rehospitalization.35 In the CHARM study,
diabetes mellitus predicted increased HF hospitalizations in
both HFpEF and HFrEF cohorts. These increased hospitaliza-
tions result in increased morbidity and costs, lending further
evidence to the deleterious effects of diabetes mellitus in this
fragile HF population and the need for adequate prevention,
screening, and management of diabetes mellitus.
We found that the most common causes of cardiovascular
deaths in patients with HF were the same in those with or
without diabetes mellitus (namely, SCD, followed by HF-
related events). This is consistent with outcomes in the I-
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PRESERVE38 trial. Patients with HF and diabetes mellitus were
not receiving optimal medical therapy for HF or diabetes
mellitus. The uptake of angiotensin-converting enzyme
inhibitors/angiotensin II receptor blockers and mineralocor-
ticoid receptor antagonists was lower in patients with
diabetes mellitus than in those without, despite good safety
data and proven benefits. Uptake of metformin was fairly low,
despite current guidelines that recommend metformin as the
first-line agent unless contraindicated as well as good safety
data of metformin in HF. Furthermore, the use of dipeptidyl
peptidase-4 inhibitors was not uncommon (>10%), despite
safety concerns of increased cardiovascular events and HF
hospitalizations. ASIAN-HF Registry enrollment occurred
before the widespread availability of sodium-glucose cotrans-
porter-2 inhibitors in Asia, and it would be interesting to
examine more recent trends in antidiabetic therapy. We have
previously shown that HF guideline-directed medical therapies
were underused in our Asian patients, emphasizing the need
for a multipronged approach to increase patient/physician
education and targeted public health strategies to improve
access and availability to these therapies for better patient
outcomes in Asia.39
Limitations
First, we acknowledge the potential for selection bias with
inclusion of predominantly academic investigators. Treatments
and outcomes reported may, therefore, reflect the best practice
in each region. Second, the lack of uniform screening using
glycated hemoglobin or oral glucose tolerance tests may have
led to underdiagnosis of diabetes mellitus. Thus, we have likely
underestimated the true burden of diabetes mellitus and its
associated adverse outcomes in our Asian countries. Further-
more, the lack of glycemic control data (glycated hemoglobin)
and proteinuria data in the registry did not allow for assessment
of diabetes mellitus control as well as complete range of
microvascular complications on outcomes. We did, however,
include other microvascular complications, like nephropathy,
retinopathy, and neuropathy. Third, this was a predominantly
Asian cohort and excluded subjects with midrange ejection
fraction (EF 40%–49%), which may potentially affect the
generalizability of the results. Finally, the observational nature
of our study precludes conclusions on causality. Despite
adjustment for multiple variables, unaccounted confounders
may potentially influence the results. Nevertheless, our results
about the relationship between diabetes mellitus and LV
remodeling may be regarded as hypothesis generating.
Conclusions
Among patients with HFrEF and HFpEF, type 2 diabetes
mellitus is associated with smaller indexed LV diastolic
volumes, higher LV filling pressures, poorer QoL, and worse
cardiovascular outcomes, with several differences noted
between HF phenotypes.
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